Open AccessDevelopment and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy
Author(s) -
Dandan Wang,
Kai Ma,
Wuguo Deng,
Jingyu Li,
ShaoHua Xiang,
Yang Zhang,
Ying Fu,
Heng Dai,
Bingding Huang
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s299381
Subject(s) - targeted therapy , precision medicine , computational biology , dna sequencing , copy number variation , precision oncology , genomics , medicine , bioinformatics , gene , genetics , cancer , biology , genome , pathology
The ability to rapidly, inexpensively, and accurately identify cancer patients based on actionable genomic mutations in tumour specimens is becoming critically important in routine clinical diagnostics. Targeted panel sequencing is becoming popular because it enables comprehensive and cost-effective diagnosis. However, the implementation of a next-generation sequencing (NGS) assay in clinical settings requires careful analytical validation to demonstrate its ability to detect multiple genomic variants.